#United States #New York #Rosen Law Firm #Securities Class #Soleno Therapeutics

Investors Encouraged to Investigate Soleno Therapeutics Class Action Claims by Rosen Law Firm

Rosen Law Firm Investigates Soleno Therapeutics for Securities Claims

The Rosen Law Firm, a prominent global law firm advocating for investors' rights, has launched an investigation regarding possible securities claims for shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). This investigation arises from reports suggesting the company may have provided materially misleading business statements that could have influenced investors’ decisions.

Background on the Investigation

The firm aims to assist those who have purchased Soleno Therapeutics securities in seeking compensation without incurring any upfront costs. Typically, a contingency fee arrangement applies, meaning legal fees are only collected if the case is won. By joining the anticipated class action, investors can take an active step to recoup potential losses associated with their investments.

On August 15, 2025, Soleno Therapeutics faced significant scrutiny following a report by Scorpion Capital that cast doubt on the efficacy and safety of its recently approved treatment for Prader-Willi syndrome, VYKAT XR. The report triggered a notable decline in the company’s stock price, which plummeted 7.4% on the critical day, followed by an additional 4.9% drop in the following trading session.

Investors reacting to this alarming news might want to explore their legal options to recover from losses sustained during this turbulent period.

Next Steps for Investors

To participate in the class action, shareholders can visit the Rosen Law Firm's website, where they can submit required information. Alternatively, investors may contact Phillip Kim, Esq., at the firm by calling their toll-free number or through email to inquire more about joining the class action.

Understanding the Rosen Law Firm's Credentials

Rosen Law Firm encourages investors to select counsels who have demonstrated a successful track record, particularly in securities class actions. They emphasize that not all firms offering similar services hold comparable resources or expertise in litigating such complex cases. The firm's history speaks for itself, having once achieved the largest securities class action settlement involving a Chinese company and consistently being recognized among the top law firms for achieving settlements in this field.

With a firm foundation and proven capabilities, the Rosen Law Firm is well-positioned to handle the complexities of securities class actions, having secured over $438 million for investors in 2019 alone. Their founding partner, Laurence Rosen, has also received accolades for his outstanding contributions to investor advocacy, being named a Titan of the Plaintiffs' Bar by Law360.

Investors should not hesitate to seek legal assistance and ensure they are represented by a law firm with extensive experience and dedicated resources, particularly in the face of allegations concerning misleading information from a publicly traded company like Soleno Therapeutics.

For updates regarding this ongoing investigation, investors can follow the firm on social media platforms such as LinkedIn, Twitter, and Facebook.

This ongoing investigation reflects a commitment to holding companies accountable for their statements and ensuring that shareholder interests are effectively represented and protected against misleading corporate conduct. Shareholders of Soleno Therapeutics are encouraged to act swiftly to explore their rights and potential recourse through this emerging class action.